Details for Patent: 8,714,149

Which drugs does patent 8,714,149 protect, and when does it expire?

Patent 8,714,149 protects AIRDUO DIGIHALER, AIRDUO RESPICLICK, ARMONAIR DIGIHALER, and ARMONAIR RESPICLICK, and is included in two NDAs.

Protection for AIRDUO DIGIHALER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-one patent family members in twenty-eight countries.

Summary for Patent: 8,714,149

Title:	Airflow adaptor for a breath-actuated dry powder inhaler
Abstract:	An airflow adaptor for a breath-actuated dry powder inhaler. The airflow adaptor includes a conduit having a proximal end and a distal end, wherein the proximal end allows fluid communication from a deagglomerator outlet port to the distal end of the conduit, and wherein the airflow adaptor further includes provisions for allowing air to flow from a proximal end of the adaptor to a distal end of the adaptor independently of the airflow in the conduit when a breath induced low pressure is applied to the distal end of the airflow adaptor.
Inventor(s):	Blair; Julian Alexander (Stradbally, IE), Buck; Daniel (Waterford, IE), Hazenberg; Jan Geert (Kilkenny, IE), Zeng; Xian-Ming (London, GB)
Assignee:	Norton Healthcare Limited (West Yorkshire, GB)
Application Number:	12/941,204
Patent Claim Types: see list of patent claims	Delivery;

Drugs Protected by US Patent 8,714,149

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-004	Jul 12, 2019		RX	Yes	No					Y
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-005	Jul 12, 2019		RX	Yes	No					Y
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-006	Jul 12, 2019		RX	Yes	No					Y
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017		RX	Yes	No					Y
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-002	Jan 27, 2017		RX	Yes	No					Y
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,714,149

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0919465.5	Nov 6, 2009

International Family Members for US Patent 8,714,149

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010314369
Australia	2014201778
Australia	2017204342
Brazil	112012010354
Canada	2779347
Chile	2012001158